their entrapment in the lung, liver and spleen. 6, 7 However, this experimental fact is based on the data obtained on rodents (mice, rats). We used the "therapeutic" MSCs to treat a patient with squamous carcinoma of the tongue who developed lung metastases.
. They are able to regenerate different damaged tissues. 1 There is an intensive research of the use of MSCs in the tissue regeneration and the disease treatment, which is performed on animals, mainly rodents. Moreover, it has been shown that in rodents (mice, rats), the MSCs migrate directly to the damaged, inflamed areas, including tumours. 2, 3 This phenomenon has been used to prepare "therapeutic" MSCs. The "therapeutic" MSCs are genetically modified MSCs that contain stable gene coding for protein or enzyme product able to kill the tumour cells. An example of such construct is the yeast enzyme cytosine deaminase, which converts the rather non-toxic 5-fluorocytosine to the cytostatic agent 5-fluorouracil. In the presence of 5-fluorocytosine, the MSCs, which (in rodents) invade in the tumour, were able to kill the tumour cells and to "cure" the animals. 4 This therapeutic concept became known as the "stem cell-based cancer gene therapy". 5 The main "ideological"
obstacle of the MSC use (normal or genetically modified) is the observation that the intravenous infusion of MSCs generally leads to their entrapment in the lung, liver and spleen. 6, 7 However, this experimental fact is based on the data obtained on rodents (mice, rats). We used the "therapeutic" MSCs to treat a patient with squamous carcinoma of the tongue who developed lung metastases.
There was no sign of any therapeutic effect after intravenous (not local, ie intratumour) administration of the "therapeutic" MSCs. (The CT scan performed on day +6 (the "therapeutic" MSCs were applied on the day 0) showed no difference in the size or density of the patients' pulmonary metastases compared to the CT scan on day À1. On the day +40, there were signs of a progression of the metastases on the CT scan.) After the intravenous administration, the "therapeutic" MSCs were "homing" in the bone marrow. Even a rather low cell count was able to cause grade 2 thrombocytopenia and grade 3 neutropenia, respectively. 8 We conclude that there has not been any entrapment of the "therapeutic" MSCs in the lungs.
Nor the cells were homing in tumour metastases. However, even a small number (60 9 10 6 cells) of the "therapeutic" MSCs were able to cause a deep temporal bone marrow suppression. We have performed a treatment of another patient with metastatic (liver, retroperitoneum, abdominal wall) ovarian carcinoma. The "therapeu- 
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